Iconovo mentioned in Biostock (only in Swedish)
Ny avtalspartner och miljonintäkt för Iconovo
Gårdagskvällen bjöd på två nyheter från lundabaserade Iconovo som utvecklar inhalatorer med tillhörande…
CBC Corporation (Private) Ltd. takes over development of Iconovo AB’s generic Symbicort project
Iconovo AB (“Iconovo”) today announced that CBC Corporation (Private) Ltd. (“CBC”) will take over the development of generic SymbicortÓ (budesonide+formoterol)…
Iconovo is ready for the next big step in the inhalation market (only in Swedish)
Iconovo är redo för nästa stora steg på inhalationsmarknaden
I slutet på januari stod det klart att EUs patentmyndighet har för avsikt att godkänna…
MARKET ANALYS OF ICONOVO BY ERIK PENSER BANK (ONLY IN SWEDISH)
Analys från Penser access:
Iconovo - USA-marknaden öppnar upp sig. Läs vidare här
Analytical Chemist for Development of Medicinal Inhalers
Iconovo is hiring an Analytical Chemist to strengthen the full development cycle of medicinal inhalers and inhalation formulations.
You are at the beginning…
ROGER LASSING JOINS ICONOVO AS VP BUSINESS DEVELOPMENT
Iconovo strengthens the sales and business development organization to meet the increased customer demand and to launch the growing product portfolio.…
GOOD NEWS FROM EPO
The European Patent Organization, EPO, has announced its intention to approve (Intention to Grant) a patent for Iconovo's inhaler platform, ICOres.
Iconovo…
Iconovo mentioned in Biostock (only in Swedish)
Iconovos inhalatorer vinner mark när konkurrerande produktpatent löper ut
Med sina inhalationsprodukter adresserar Lundabolaget Iconovo ett marknadsvärde…
Iconovo Newsletter 2018
News and inspiration by Iconovo December 2018.
Iconovo will be attending DDL2018 in Edinburgh, be sure to stop by the Iconovo stand - number 300 - and…
Iconovo receives a significant order from Japanese TOA Pharmaceuticals Co., Ltd.
Iconovo receives a significant order from Japanese TOA Pharmaceuticals Co., Ltd.
The innovative Swedish medical technology provider Iconovo AB announced…
